ROTEIN C is a vitamin K-dependent blood coagulation inhibitor playing an important role in the protein C anticoagulant pathway, as attested to by thrombotic disorders in patients with hereditary deficiencies."' Protein C is encoded by a gene located on chromosome 2, at position 2q13-q21,4-6 spanning 11.6 kb' and comprising 9 exons,' the first of which is not translated. The intron-exon organization of the gene reflects the structural protein domain partition, as in the case of other vitamin K-dependent proteins such as factors IX and X and suggests that exons are associated by shuffling.' Exon I1 encodes the signal peptide, exon 111 the propeptide and Gla domain, exon IV a short helical aromatic stretch, exons V and VI each encode an epidermal growth factor-like domain (EGF l and EGF 2), exon VI1 encodes the linker and activation peptides, and exons VI11 and IX encode the catalytic site, the substrate hydrophobic pocket, binding sites for factor Va,"." and an exosite.I2 The protein is synthesized as a single 462-amino acid chain that undergoes several posttranslational modifications, comprising cleavage of the signal peptide and propeptide, y-carboxylation of the 9 Glu of the Gla domain, p-hydroxylation of Asp 7 1, and cleavage of the linker peptide ( L y~'~~--A r g '~~) , giving rise to a protein comprising one light and one heavy chain linked by a disulfide bridge." Protein C deficiency is inherited as an autosomal dominant trait and has variable penetrance: heterozygous patients with plasma protein C levels between 25% and 70% of normal are either symptomatic (1 of 16,000 in the general populationi4) or asymptomatic (1 of 200 to 1 of 500 of normal The wide variety of mutations suggests that both sporadic cases and a founder effect contribute to the spectrum of protein C mutations in a given population. The differences in both unique and recurrent mutations in French and Dutch populations-the only large population samples so far studied-support this hypothesis.
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When we began this study in 1990, only three mutations had been associated with protein C d e f i c i e n~y .~~-~~ Many mutations have now been described, and most are associated with quantitative (type l) deficiencies. Most deficient patients are heterozygous for a point About 15 homozybeen genotyped. With one exception:8 studies to date have involved relatively small and heterogeneous populations; the representative spectrum of mutations is only known in The Netherlands. 28 We studied 121 consecutive symptomatic French patients to establish the molecular basis of quantitative protein C deficiencies and to see whether such information may help to understand various phenotypes associated with such abnormalities. In most cases, the propositi and their relatives were referred to our group after one of these specialized centers had diagnosed a type I protein C deficiency on the basis of repeated blood sampling.
The general strategy was to screen patients with unexplained thrombosis with a coagulation assay (Staclot Protein C, Diagnostica Stago, Asnitres, France). In patients with protein C levels 570% (a lower limit admitted by all the members of the network), an amidolytic assay (Stachrom Protein C, Diagnostica Stago) was performed in most centers to confirm the diagnosis. To distinguish between type I and type I1 deficiencies, protein C levels were measured using an immunoenzymatic assay (Asserachrom Protein C, Diagnostica Stago) or a Laurel1 assay. In this assay, the lower limit was also 70%, and a ratio of activity to antigen level 2 0 . 8 was considered to reflect a type 1 deficiency.
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Whenever possible, family studies were undertaken to check that the genomic abnormalities cosegregated with protein C deficiency.
A total of 280 subjects, among whom 121 were propositi with type I protein C deficiency, were included in the study. Materials and methods. All the materials and methods used to locate and identify mutations (primer sequences, annealing temperatures, size determination of PCR products, and optimal denaturing gradient gel electrophoresis (DGGE) conditions determined using the computer programs indicated above, as well as sequencing conditions) have been described in a previous study."
RESULTS
All the coding sequences and intron-exon junctions of the gene were studied. Their cumulated length is 2,414 bp, ie, all coding base pairs, and 22% of the entire protein C gene sequence.
We detected 113 sequence variations by screening 191 individuals (121 propositi and 70 controls) by means of DGGE. Ninety-three of these variations were detected in 90 propositi and were presumably deleterious mutations (Tables 1 and 2); twenty-one were probably silent mutations ( Table  3) , as they were detected in normal subjects, did not change the encoded amino acid, were located in intronic regions, or did not cosegregate with the deficiency.
The 90 propositi with protein C sequence variations bore 55 different mutations. The sequence variations detected in the coding sequences are listed in Table 1 , those affecting the splice site sequences in Table 2 , and rare DNA polymorphisms in Table 3 We identified four splice junction sequence changes in splice donor sites of introns b, e, f, and h ( Table 2) . Three were single base substitutions at position + l , +4, or +5 (nucleotides 7257, 74, or 3222, respectively) of the consensus splice donor site sequence. The fourth was a deletion of 5 bp in intron f, deleting nucleotides +2 to +6 and thus destroying the consensus splice site sequence. Family studies showed that the mutation occurred de novo.& In addition, two patients (No. 080 and No. 113) had a single base substitution in exon V, at position -2 of the splice donor site.
A total of 42 different missense mutations were identified in 70 patients. Table 1 shows their wide heterogeneity. Surprisingly, we found a -5 Arg to Trp mutation in one patient with a type I deficiency; indeed, this has been described as the only nucleotide change in the coding region in a patient with a type I1 deficiency.m Similarly, the Asp 35 to Gly mutation was also detected in a patient with a type I1 deficiency (unpublished results).
Whenever possible (51 of 90 cases), cosegregation of the genomic abnormality with the plasma protein C deficiency was checked by studying the families ( Tables 1 and 2) .
Rare DNA polymorphisms. A total of 14 DNA sequence polymorphisms were identified. Six were located in introns and were identified in normal subjects (nt -1394, G>A; nt 61 17, C>T; deletion of nt 7086 to 7090), did not cosegregate with a deficiency (nt -1378, G>C; nt -26, C>A), or were associated with a detrimental mutation in the coding region (nt 77, C>G&).
The other polymorphisms were located in coding regions and did not change the encoded amino acid (nt 3381, G>A; nt 6217, C>A; nt 8513, C>T; nt 8750, T>C; nt 8759, C>T; and nt 8801, G>A), with the exception of mutation Met 343 to Ile (nt 8744, G>T), detected in a subject with normal protein C levels (86%, 78%, 90% of antigen, amidolytic activity, and anticoagulant activity, respectively), and Gly 370 to Ser (nt 8823, G>A), which did not cosegregate with the deficiency.
Relationship between genotypes and plasma phenotypes. The 121 subjects recruited for this study were symptomatic patients referred to specialized centers for unexplained thrombosis. The diagnosis of hereditary protein C deficiency was made after clinical and laboratory investigations, as described in Materials and Methods.
The genomic analysis confirmed the diagnosis in 90 of 121 propositi (74%). Most (82, 68%) had protein C levels between 14% and 60% (coagulation assay), among whom 75 were heterozygous for a protein C gene mutation, I( Double mutant IF76 -+ U314 R -+ H) in a compound heterozygous subject with type I and type II deficiency (type I 1 due to a 9 R -+ C mutation). antigen, amidolytic, and coagulant assays were respectively Among the 31 propositi with no identified abnormality in nd/15%/nd in patient 044, 22%/16%/16% in patient 057, the protein C gene coding sequence, 15 had protein C levels 16%/15%/26% in patient 019, and 47%/56%/14% in patient between 6 0 % and 70% (coagulation assay). In this latter 080 (compound heterozygote for type I and type I1 deficiengroup, familial studies was either impossible (10 propositi) cies) .
or did not show a protein C deficiency in the relative ex- 
DISCUSSION
Genomic analysis of 121 consecutive French patients with a type I protein C deficiency allowed us to detect 55 different mutations in 90 patients (74%). Large deletions or insertions, which cannot be detected by our approach, remain to be sought in the 31 patients in whom we did not detect point mutations.
These mutations cosegregated with the protein C deficiency when family studies were possible (51 families) and none were found in the protein C gene of 70 controls with normal protein C levels. Thus, the 55 mutations identified in this series probably have a detrimental effect on the expression of the corresponding allele.
Eight changes were nonsense mutations or frameshifts, which generate a truncated polypeptide chain or alter the reading frame, generating stop codons or aborted proteins, respectively. Frameshifts frequently introduce premature stop codons, but one frameshift in this series shifted the stop codon from codon 420 to codon 462, theoretically giving rise to an elongated protein. Immunoblotting failed to show an abnormal protein in the patient's plasma, suggesting that the polypeptide, if synthesized, was not secreted. It is noteworthy that all the patients, but one (No. 016), with nonsense or frameshift mutations had protein C levels below 60%.
Splice site mutations (five in our series) are deleterious, as they destroy the conserved positions of the consensus splice site sequences and impair mRNA splicing, a mechanism known to impair translation. Two patients (pedigrees No. 080 and 113) were heterozygous for a C and T (nucleotide 3216) at position -2 of the donor splice site of exon V. Even if this apparently silent mutation did not change the amino acid (Arg), a detrimental effect due to abnormal mRNA stability or to exon skipping cannot be ruled out. The latter was recently described in the case of mutations occurring at position -1 of the donor splice site of exon VI1 of the protein C gene36 and at position -3 of those of exon 28 of the GP IIb-IIIa gene.61 Studies of mRNA structure and expression will help clarify this issue. The detrimental effect of the 42 missense mutations is more difficult to ascertain.
Some of the mutations involved amino acids with key positions; for example, Gln -40 and Leu -34 form part of the signal sequence of protein C, which is necessary for translocation of the neosynthesized chain into the endoplasmic reticulum"~63; Gln -40 belongs to the n-region, and its Amlnoacklnumbor substitution by a hydrophobic and helix-breaking Pro may diminish the stability of the domain; Leu -34 is part of the hydrophobic core (h-region) and belongs to the polyleucine sequence. Hydrophobicity does not change when Leu is replaced by Pro, but the helix-breaking effect may again impair the signal peptide conformation and, thus, translocation of the polypeptide chain.
Other mutations affected amino acids highly conserved in protein C of mammalian species, such as Pro 54, 168, 279, and 327, or in protein C of mammals and other vitamin Kdependent proteins (factors 11, VII, IX, and X)"69 such as substitutions affecting Gly 67, 197, and 361, attesting to the structural importance of these amino acids.
It is noteworthy that 62% (26 of 42) of the missense mutations in this series involved only 5 of the 20 existing amino acids (Cys, Phe, Trp, Gly, and Pro). These 5 amino acids are known to affect the structure of the polypeptide chain by various mechanisms. Mutations affecting Cys or introducing new Cys residues in the sequence may disrupt the secondary structure or impair the folding or intracellular trafficking by homodimerization or heterodimerization. Mutations affecting Phe, Trp, and Gly or introducing these residues disturb the structure of the polypeptide chain by a difference in bulk between the normal and the mutated amino acid. Finally, mutations involving Pro may disrupt the structure of the polypeptide chain by modifying the rigidity of the chain through a helix-or &sheet breaking effect.
On the basis of a three-dimensional model, Greengard et a17' recently proposed explanations for the detrimental effect of six mutations detected in this series (Arg 169 to Trp, Arg 178 to Trp or Gln, Ala 267 to Thr, Thr 298 to Met, and Ile 403 to Met).
We have only indirect arguments for a detrimental effect of mutations Ala 209 to Val, Gln 293 to His, Val 297 to Met, Thr 298 to Lys, Arg 314 to His, Met 335 to Thr, Asn 389 to Lys, and Ile 403 to Leu. All these amino acids are conserved among nine mammalian protein C species and are thus structurally important. None were detected in the panel of 70 normal subjects. Site-directed mutagenesis and expression studies could help to establish whether or not these mutations are detrimental.
The location of the mutations is shown in Fig 1. They cated on the upper barrel.
occurred throughout the sequence, although two domains, encoded by exon VI1 and the 5' half of exon IX, appear to be preferential sites for mutations. Such a large spectrum of mutations in patients living within the same geographic area suggests a high rate of de novo mutations. The finding of two sporadic cases in a series of 40 families studied4' supports this hypothesis. Subjects heterozygous for a protein C gene mutation have late clinical expression38 or remain asympt~matic,'~,'~ which allows their genomic abnormality to be transmitted to their descendents. This probably explains why 17 mutations are apparently recurrent and account for type I protein C deficiencies in 54 (60%) of the 90 propositi bearing a point mutation of the protein C gene coding sequence.
The spectrum of recurrent mutations in the French population is completely different from that found in The Netherlands, where the most frequent mutations affect Gln 132 and Arg 230, rather than Arg 178 and Pro 168 in the French population. Interestingly, the Leu 223 to Phe mutation, preferentially found in the north of France,56 has also been described in Dutch patients." A founder effect probably explains the differences between these two populations.
Among the French patients with point mutations, 76% bore a missense mutation, the remainder being accounted for by frameshifts and nonsense or splice site mutations.
These results are consistent with those reported in the literature, particularly those in the database?' The proportion of missense mutations is very high and the spectrum very wide, making the molecular basis for protein C deficiencies very similar to that of factor IX deficiencies causing hemophilia B." However, the mode of inheritance of protein C deficiency is much more complex than that of hemophilia B.
Although the probability of compound heterozygosity and homozygosity is low, we identified complex genotypes in four subjects (4.4%). Two were compound heterozygotes for type I deficiencys6 or for a combined type I and I1 deficiency.
In the latter case, the patient had an allele bearing an Arg 9 to Cys mutation (responsible for type I1 deficiency), whereas the other allele was doubly mutated with Phe 76 to Leu and Arg 314 to His substitutions, both of which are known to be associated with type I deficiency in heterozygous sub-
.~~. "
We identified Pro 168 to Leu and Gly 292 to Ser mutations in both homozygous (No. 044 and 057) and symptomatic heterozygous patients. Mutations Ala 267 to Thr and Arg 286 to Cys, observed in symptomatic heterozygous propositi, had already been described in homozygous patient~.~'"~ Thus, parents of homozygous subjects bear mutations that can lead to thrombotic complications, even in heterozygous subjects.
We also observed a double mutation in patient No. 045, who had an alieie bearing Ala 209 to Val and Arg 178 to Gln substitutions. This doubly mutant genotype probably explains the phenotype of two subjects with Arg -5 to Trp or Asp 35 to Gly mutations, which are associated with type I1 deficiencies in other patients@ (unpublished results). The allele bearing these mutations might also bear a large deietion or insertion, precluding the expression of the allele and giving rise to a type I deficiency.
The wide variety of missense mutations may explain the heterogeneity of the plasma phenotype and clinical expression of protein C deficiency. Recent reports of mutations in homozygous s u b j e~t s~~-'~ and mutation expression experim e n t~~'~'~ show that some missense mutations are associated with a total absence of gene expression, while others permit partial gene expression and secretion of a small quantity of protein. T h i s is reminiscent of n,-antitrypsin deficiencies, in which some mutations cause a null phenotype and others a plus phenotype.
The absence of mutations in 3 1 (24%) patients underlines the difficulty of diagnosing hereditary protein C deficiency. Large gene rearrangements have never been well documented and, if they exist, could not explain the low protein C levels observed in all 31 propositi. Our strategy to detect point mutations is based on DGGE, the most sensitive screening method for point mutation^.'^ It was carefully set up and tested with known mutations,* making it unlikely that nucleotide substitutions were missed in as many as 24% of the patients. Half the propositi with no mutations had protein C levels between 60% and 70% and thus might be normal. The overlapping values observed in normal and heterozygous subjects:' as well as intraindividual fluctuations in protein C concentrations,16 suggest that a sizeable proportion of patients in our series were misclassified. Genomic analysis is thus a valuable diagnostic tool in some cases of ambiguous plasma phenotypes.
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